The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Alere beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP loss per share dropped.
Gross margins were steady, operating margins improved, net margins increased.
Alere recorded revenue of $651.1 million. The 12 analysts polled by S&P Capital IQ looked for sales of $631.6 million. GAAP sales were 13% higher than the prior-year quarter's $578.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.74. The 13 earnings estimates compiled by S&P Capital IQ anticipated $0.71 per share on the same basis. GAAP EPS were -$4.62 for Q4 compared to -$12.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 52.4%, about the same as the prior-year quarter. Operating margin was 6.0%, 970 basis points better than the prior-year quarter. Net margin was -55.3%, 12,330 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $648.6 million. On the bottom line, the average EPS estimate is $0.66.
Next year's average estimate for revenue is $2.62 billion. The average EPS estimate is $2.69.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Alere is outperform, with an average price target of $31.20.
Over the decades, small-cap stocks, like Alere have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Alere to My Watchlist.
More from The Motley Fool
Why Straight Path Communications, Alere, and MoneyGram International Jumped Today
These stocks helped lead the market higher. Find out why.
Alere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories
Despite a lower price, Abbott's agreement to acquire Alere Inc. gives shareholders a reason to cheer.
Alere Inc. Has Been Left for Dead, With Its Shares Down 13%
Poor Q3 results combined with allegations of submitting claims for deceased patients equals a bad day.